A global leading IVD (in vitro diagnostics) company has its main business in hematology, hematosis, urinalysis, immunochemistry, and clinical chemistry with over $3B in net sales. Regarding their Digital Healthcare Section, the office is in the Bay Area in Northern California and is scouting for opportunities in North America, from startups to co-development and co-investment, to compliment the firm’s internal product portfolio (e.g. blood biomarkers) and expand their digital healthcare business. Equity investments are made on a case-by-case basis, but when applicable, the corporation is looking for companies generally in Series A and B rounds with typical check size ranging from $1-10M USD. The corporation will also provide commercialization support in Japan and overseas markets.
The firm is currently looking for companies that strategically align with their main business as well as (1) finding digital technologies that can assist with patient stratification and early risk identification to increase testing volume on the firm’s IVD tests (early identification), (2) digital therapeutics that can increase the value of diagnostics, and (3) enter new areas of homecare by utilizing blood biomarker assets and digital solutions. Subsectors include, but are not limited to, digital health, home care, digital therapeutics, digital biomarkers, and clinical decision support. Companies should typically be conducting clinical trials however, pre-clinical stages may be of considered. Interested indications are CNS diseases, cardiovascular diseases, lifestyle diseases (e.g. hypertension), mental health, and chronic kidney diseases.
The firm does not have specific management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment